These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 2198812)

  • 1. A double-masked three-month comparison between 0.25% betaxolol suspension and 0.5% betaxolol ophthalmic solution.
    Weinreb RN; Caldwell DR; Goode SM; Horwitz BL; Laibovitz R; Shrader CE; Stewart RH; Williams AT
    Am J Ophthalmol; 1990 Aug; 110(2):189-92. PubMed ID: 2198812
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A comparison of the safety and efficacy of twice daily brimonidine 0.2% versus betaxolol 0.25% in subjects with elevated intraocular pressure. The Brimonidine Study Group III.
    Serle JB
    Surv Ophthalmol; 1996 Nov; 41 Suppl 1():S39-47. PubMed ID: 8970248
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A double-masked randomized comparison of the efficacy and safety of unoprostone with timolol and betaxolol in patients with primary open-angle glaucoma including pseudoexfoliation glaucoma or ocular hypertension. 6 month data.
    Nordmann JP; Mertz B; Yannoulis NC; Schwenninger C; Kapik B; Shams N;
    Am J Ophthalmol; 2002 Jan; 133(1):1-10. PubMed ID: 11755834
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of the clinical success rates and quality of life effects of brimonidine tartrate 0.2% and betaxolol 0.25% suspension in patients with open-angle glaucoma and ocular hypertension. Brimonidine Outcomes Study Group II.
    Javitt J; Goldberg I
    J Glaucoma; 2000 Oct; 9(5):398-408. PubMed ID: 11039742
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ocular hypotensive efficacy and safety of a combined formulation of betaxolol and pilocarpine.
    Robin AL
    Trans Am Ophthalmol Soc; 1996; 94():89-101; discussion 101-3. PubMed ID: 8981691
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Clinical evaluation of betaxolol in ophthalmic suspension with or without preservative agent in patients with glaucoma or ocular hypertension].
    Denis P; Demailly P; Saraux H
    J Fr Ophtalmol; 1993; 16(5):297-303. PubMed ID: 8331248
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Are there any benefits of Betoptic S (betaxolol HCl ophthalmic suspension) over other beta-blockers in the treatment of glaucoma?
    Yarangümeli A; Kural G
    Expert Opin Pharmacother; 2004 May; 5(5):1071-81. PubMed ID: 15155109
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Longterm effect of topical beta-blockers on intraocular pressure and visual field sensitivity in ocular hypertension and chronic open-angle glaucoma.
    Collignon-Brach J
    Surv Ophthalmol; 1994 May; 38 Suppl():S149-55. PubMed ID: 7940136
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of topical betablockers on human retinal vessels diameters.
    Collignon NJ; Collignon-Brach JD
    Int Ophthalmol; 1997-1998; 21(4):199-203. PubMed ID: 9700006
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Betaxolol hydrochloride ophthalmic suspension 0.25% and timolol gel-forming solution 0.25% and 0.5% in pediatric glaucoma: a randomized clinical trial.
    Plager DA; Whitson JT; Netland PA; Vijaya L; Sathyan P; Sood D; Krishnadas SR; Robin AL; Gross RD; Scheib SA; Scott H; Dickerson JE;
    J AAPOS; 2009 Aug; 13(4):384-90. PubMed ID: 19683191
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The long-term safety and efficacy of brinzolamide 1.0% (azopt) in patients with primary open-angle glaucoma or ocular hypertension. The Brinzolamide Long-Term Therapy Study Group.
    March WF; Ochsner KI
    Am J Ophthalmol; 2000 Feb; 129(2):136-43. PubMed ID: 10682964
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A double-masked comparison of betaxolol and dipivefrin for the treatment of increased intraocular pressure.
    Albracht DC; LeBlanc RP; Cruz AM; Lamping KA; Siegel LI; Stern KL; Kelley EP; Stoecker JF
    Am J Ophthalmol; 1993 Sep; 116(3):307-13. PubMed ID: 8357055
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The favorable effect of topical betaxolol and timolol on glaucomatous visual fields: a 2-year follow-up study.
    Vainio-Jylhä E; Vuori ML
    Graefes Arch Clin Exp Ophthalmol; 1999 Feb; 237(2):100-4. PubMed ID: 9987624
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Short-term clinical trial evaluating the efficacy of the combination of apraclonidine 0.5% solution and betaxolol 0.25% suspension.
    Lamberti G; Pignalosa B; Fusco R; Pignalosa G; Di Govanni A; Sebastiani A
    Acta Ophthalmol Scand Suppl; 1997; (224):20-1. PubMed ID: 9589713
    [No Abstract]   [Full Text] [Related]  

  • 15. Low incidence of iris pigmentation and eyelash changes in 2 randomized clinical trials with unoprostone isopropyl 0.15%.
    McCarey BE; Kapik BM; Kane FE;
    Ophthalmology; 2004 Aug; 111(8):1480-8. PubMed ID: 15288975
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of betaxolol on primary open-angle glaucoma and normal-tension glaucoma patients.
    Saccà SC; Macrì A; Rolando M; Ciurlo G
    J Ocul Pharmacol Ther; 1998 Jun; 14(3):191-201. PubMed ID: 9671427
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical efficacy and safety of brinzolamide (Azopt), a new topical carbonic anhydrase inhibitor for primary open-angle glaucoma and ocular hypertension. Brinzolamide Primary Therapy Study Group.
    Silver LH
    Am J Ophthalmol; 1998 Sep; 126(3):400-8. PubMed ID: 9744373
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of combined administration of 0.2% brimonidine and 0.5% betaxolol in treatment of primary open angle glaucoma and ocular hypertension.
    Chi W; Li A; Wang S; Zhu X
    Eye Sci; 2013 Dec; 28(4):190-4. PubMed ID: 24961091
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The one-month effects of topical betaxolol, dorzolamide and apraclonidine on ocular blood flow velocities in patients with newly diagnosed primary open-angle glaucoma.
    Avunduk AM; Sari A; Akyol N; Oztürk O; Kapicioglu Z; Erdöl H; Imamoglu HI
    Ophthalmologica; 2001; 215(5):361-5. PubMed ID: 11528262
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of the clinical success and quality-of-life impact of brimonidine 0.2% and betaxolol 0.25 % suspension in patients with elevated intraocular pressure.
    Cantor LB; Hoop J; Katz LJ; Flartey K;
    Clin Ther; 2001 Jul; 23(7):1032-9. PubMed ID: 11519768
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.